Share

Profile & Fundamentals

UCB Profile & Fundamentals

Name: UCB financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Company profile record

UCB SA

Common Stock · Health Care · Pharmaceuticals

Official website

Company

Company / asset: UCB SA
Security type: Common Stock
Sector: Health Care
Industry: Pharmaceuticals
HQ: 🇧🇪 Belgium
Head office: Allée de la Recherche, 60, Brussels, Belgium, 1070

Leadership & scale

Chief executive: Dr. Jean-Christophe Tellier
CEO year born: 1959
Full-time employees: 9K
Fiscal year end: December

Fundamentals snapshot

Updated 2026-08-12

Market Cap: EUR 39.5B
P/E: 11.2x
Revenue (Q2 26): EUR 4.3B
Profit (Q2 26): EUR 1.1B
Dividend Yield: 0.8%
Revenue (FY 25): EUR 7.7B
Shares in public float: 119.6M
Insider ownership: 36.28%

Reporting & identifiers

Symbol: UCB.BRU
Listing: 🇧🇪 Belgium | Dividend Tax: 30%
Ticker Currency: EUR
Income Statement Currency: EUR
Balance Sheet Currency: EUR
Cash Flow Currency: EUR
EPS Currency: EUR
Contract Type: SPOT
ISIN: BE0003739530
Asset ID: equity_e159b6d2-aa08-54db-9484-af8443d74188

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company's financial performance is exceptionally strong, marked by a massive 25.8% jump in revenue and a doubling of its free cash flow in 2025. This explosive growth shows that the company has successfully moved past the threat of older drugs losing their patents and is now reaping huge rewards from its new immunology treatments. Analysts agree that the company is generating high-quality, real cash flows rather than relying on accounting tricks. However, there is some disagreement about the future profit outlook. Some experts warn that recent expensive company purchases and the high costs of competing in the US market will temporarily squeeze profits over the next few years. Others believe the sheer volume of new drug sales will easily overpower these costs, keeping the company on a highly profitable path. Overall, the financial trend is highly positive and supportive of long-term growth.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

The company enjoys outstanding profitability, with gross margins holding steady at a remarkable 71%. This means the company has immense pricing power and its products are highly profitable to make. However, there is a clear clash of opinions regarding the future direction of operating margins. Some analysts are highly optimistic, believing that as sales of its blockbuster skin drug scale up globally, profit margins will naturally expand toward the mid-20% range. Conversely, more cautious observers warn that the company faces a temporary margin squeeze. They point to the high costs of integrating recent acquisitions and the intense marketing battles required to fight off large competitors in the US. While the current stock price reflects a premium for this profitability, the general consensus is that the company's margins are highly resilient and well-protected against inflation, making it a very attractive defensive investment.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-08-13.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2016-12-31	4,395,820,000	338,140,000	551,200,000	71.02	19.19	12.54	7.69
2017-12-31	5,324,060,000	984,130,000	896,070,000	73.18	24.03	16.83	18.48
2018-12-31	5,280,480,000	1,134,300,000	912,000,000	74.14	24.01	17.27	21.48
2019-12-31	5,502,560,000	658,560,000	887,040,000	70.95	22.06	16.12	11.97
2020-12-31	6,523,340,000	893,040,000	893,040,000	71.24	18.27	13.69	13.69
2021-12-31	6,585,780,000	1,208,400,000	1,206,120,000	72.1	19.85	18.31	18.35
2022-12-31	5,903,190,000	800,360,000	447,260,000	66.23	7.25	7.58	13.56
2023-12-31	5,777,200,000	489,500,000	377,300,000	67.5	11.5	6.53	8.47
2024-12-31	6,398,080,000	956,800,000	1,107,600,000	71.52	21.52	17.31	14.95
2025-12-31	9,056,970,000	2,201,940,000	1,822,860,000	71.14	15.06	20.13	24.31

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	17.28	Trailing four quarters
2024-12-31	26.54	Trailing four quarters
2022-12-31	33.82	Annual net income
2021-12-31	18.39	Annual net income

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	188,309,100
2018-01-01	188,484,000
2019-01-01	188,583,000
2020-01-01	199,604,200
2021-01-01	193,883,700
2022-01-01	192,175,900
2023-01-01	199,618,200
2024-01-01	194,435,600
2025-01-01	189,997,000
2026-01-01	189,997,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.